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Mesenchymal stem cells (MSCs) possess pleiotropic properties that include immunomodulation, inhibition of apoptosis, fibrosis
and oxidative stress, secretion of trophic factors, and enhancement of angiogenesis. These properties provide a broad spectrum for
their potential in a wide range of injuries and diseases, including diabetic nephropathy (DN). MSCs are characterized by adherence
to plastic, expression of the surface molecules CD73, CD90, and CD105 in the absence of CD34, CD45, HLA-DR, and CD14 or
CD11b and CD79a or CD19 surface molecules, and multidifferentiation capacity in vitro. MSCs can be derived from many tissue
sources, consistent with their broad, possibly ubiquitous distribution. This article reviews the existing literature and knowledge
of MSC therapy in DN, as well as the most appropriate rodent models to verify the therapeutic potential of MSCs in DN setting.
Some preclinical relevant studies are highlighted and new perspectives of combined therapies for decreasing DN progression are
discussed. Hence, improved comprehension and interpretation of experimental data will accelerate the progress towards clinical
trials that should assess the feasibility and safety of this therapeutic approach in humans. Therefore, MSC-based therapies may
bring substantial benefit for patients suffering from DN.
1. Introduction
Diabetes mellitus (DM) is a global epidemic disease that
affects people of all ages, gender, and ethnicity.Theprevalence
of DM for all age-groups was estimated to be 2.8% in 2000
and 4.3% in 2030. The total number of people with DM is
projected to rise from 171 million in 2000 to 366 million in
2030 according to World Health Organization [1].
Diabetic nephropathy (DN) is the leading cause of
chronic kidney disease in patients starting renal replacement
therapy, affecting ∼40% of type 1 and type 2 diabetic patients
[2]. DN is defined by increased urinary albumin excretion
(UAE) in the absence of other renal diseases and is cate-
gorized into the following stages: microalbuminuria (UAE
20𝜇g/min–199𝜇g/min or 30–299mg/24 h) and macroalbu-
minuria (UAE≥ 200𝜇g/min or≥300mg/24 h) [3]. In patients
with type 2 diabetes, the incidence of microalbuminuria is
2% per year and the prevalence at 10 years after diagnosis is
25% [4]. Proteinuria occurs in 15–40% of patients with type
1 diabetes, with a peak in 15–20 years after DM diagnosis [5].
Likewise, in patients with type 2 diabetes, the prevalence of
proteinuria is variable, ranging from 5 to 20% [4]. The stage
of DN has a positive association with increased mortality
of all causes and from cardiovascular, cerebrovascular, and
coronary heart diseases [4, 6].
Clinical manifestations of DN, such as proteinuria,
increased blood pressure, and decreased glomerular filtration
rate are similar in type 1 and type 2 diabetes and correlate
strongly with structural abnormalities. Morphologically, DN
is characterized by thickening of the glomerular basement
membrane (GBM) and mesangial expansion, leading to a
progressive reduction in the filtration surface of the glomeru-
lus [7]. Although the most important structural changes
occur in the glomeruli, concomitantly and approximately in
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proportion to the degree of glomerulopathy, abnormalities
in the tubule-interstitial and arteriolar compartments con-
tribute to the pathogenesis of DN [7, 8].
Despite the fact that pancreas transplant may reverse
the thickness of the glomerular and tubular basement mem-
branes after five years of normoglycemia [9], that procedure
is associated with adverse effects of immunosuppressive
regimen [10] and immunological risk that affect long-term
survival [11].
DN progression may be prevented by tight glucose con-
trol, blood pressure control, renin-angiotensin-aldosterone
system (RAAS) blockade, smoking cessation, weight loss, and
physical activity [3].
To note, mesenchymal stem cell- (MSC-) based therapies
have been expected to bring substantial benefit to patients
suffering a wide range of diseases and injuries. This article
reviews the existing literature and knowledge ofMSC therapy
in DN and highlights some preclinical relevant studies and
new perspectives of combined therapies for decreasing DN
progression.
2. The Pathogenesis of Diabetic
Nephropathy (DN)
DN is initially characterized by functional glomerular
changes, including glomerular hyperperfusion and hyperfil-
tration, before the onset of any measurable clinical changes.
As DN evolves, thickening of the GBM, glomerular hypertro-
phy, and mesangial expansion take place.
Despite the fact that several factors have been implicated
in the pathogenesis of DN, we will focus on the particular
factors outlined above [12–17]:
2.1. Hemodynamics Pathways. The early signs of glomerular
hyperperfusion and hyperfiltration result from decreased
resistance of renal arterioles (afferent > efferent) which are
mediated by prostanoids, nitric oxide, vascular endothelial
growth factor A (VEGF-A), transforming growth factor-
𝛽1 (TGF-𝛽1), endothelin, and RAAS. These effects facilitate
localized release of certain cytokines and growth factors,
leading ultimately to albumin leakage from the glomeru-
lus and structural changes, for example, overproduction of
mesangial cell matrix, thickening of GBM, and podocyte
damage.
2.2. Hyperglycemia and Advanced Glycosylation End Products.
Hyperglycemia is a key factor in developing DN due to
its effect on mesangial cell proliferation, hypertrophy, and
apoptosis, as well as an increased matrix production and
GBM thickening. These effects are mediated by upregulation
of glucose transporters (GLUT1 and GLUT4) and an increase
in glucose entrance into the cells.
Hyperglycemia mediates tissue damage by inducing
nonenzymatic glycosylation that generates advanced glyco-
sylation end products (AGEs; the cross-link with collagen
I contributes to microvascular complications), activation of
protein kinase C (PKC; activates vasodilatory prostanoids
which contributes to glomerular hyperfiltration, as well as
TGF-𝛽1), and acceleration of the aldose reductase pathway.
All these three pathways are related to oxidative stress.
2.3. Cytokines. Activation of cytokines, profibrotic and
inflammatory elements, and vascular growth factorsmight be
involved in the matrix accumulation that takes place in DN.
VEGF and angiopoetin contribute to retinopathy, although
their effects on DN are not conclusive. To note, VEGF may
increase permeability of the glomerular filtration barrier to
proteins. Hyperglycemia, TGF-𝛽1, and angiotensin II stimu-
late VEGF expression, which ultimately leads to the produc-
tion of endothelial nitric oxide and 𝛼3 chain of collagen IV.
On the other hand, VEGF might be a crucial factor secreted
by podocytes to maintain both glomerular endothelial cell
and mesangial cell proliferation and differentiation.
TGF-𝛽1 contributes to cell hypertrophy and increased
synthesis of collagen, leading ultimately to glomerulosclerosis
and tubule-interstitial injury during DN development. Hep-
atocyte growth factor (HGF) ameliorates DN by blocking the
profibrotic actions of TGF-𝛽1.
Inflammatory cytokines also contribute to the devel-
opment and progression of DN, mainly interleukin-1 (IL-
1), IL-6, IL-18, and tumor necrosis factor-𝛼 (TNF-𝛼). Each
cytokine possesses different effects. IL-1 alters the expres-
sion of chemotactic factors and adhesion molecules, alters
intraglomerular hemodynamics mediated by prostaglandins,
increases vascular endothelial cell permeability, and increases
hyaluronan production by renal tubular epithelial cells. IL-
6 promotes GBM thickening, endothelial permeability, and
mesangial expansion. IL-18 is associated with endothelial cell
apoptosis and secretion of other inflammatory cytokines (IL-
1, interferon 𝛾 [INF-𝛾], and TNF-𝛼). TNF-𝛼 affects apoptosis,
glomerular hemodynamics, endothelial permeability, and
cell-cell adhesion.
2.4. LipidMediators. Prostaglandin E2 and I2might promote
renal inflammation and renal inhibition of cyclooxygenase 2
is associated with a decrease in glomerular hyperfiltration.
Lipoxygenases 12 and 15 are also increased in DN. Further-
more, arachidonic acid oxidation might be related to mesan-
gial cell hypertrophy and extracellular matrix accumulation
by TGF-𝛽1 and angiotensin II.
2.5. Oxidative Stress. Reactive oxygen species, generated in
the mitochondria, mediate many negative biological effects,
including peroxidation of cell membrane lipids, oxidation of
proteins, renal vasoconstriction, and damage to DNA, as well
as PKC activation and AGEs formation.
2.6. Genetic Susceptibility. In patients with type 1 and type
2 diabetes, the likelihood of developing DN is increased in
those who have a sibling or parent with DN. Genotyping
single-nucleotide polymorphism investigation indicates that
some loci are identified as DN susceptibility genes areas on
chromosomes 7q21.3, 10p15.3, 14q23.1, and 18q22.3. Likewise,
association studies of candidate genes suggested that the
angiotensin-converting-enzyme gene (ACE) DD polymor-
phism might be associated with increased risk of developing
DN in type 2 diabetic patients. However, identification of a
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multigene panel seems to be the most appropriated approach
to study the susceptibility to DN.
3. Mesenchymal Stem Cells (MSCs)
MSCs, commonly referred to as mesenchymal stem cells
or mesenchymal stromal cells, are a diverse population of
cells with a wide range of potential therapeutic applications
for different organs and tissues. MSCs can be derived from
many tissue sources, consistent with their broad, possibly
ubiquitous distribution.
Stem cells are characterized by their ability to self-renew,
clone, differentiate into different lineages, and regenerate
damaged organ. The International Society for Cell Therapy
(ISCT) proposed a criteria to define human (h) MSC that
comprises the following: (1) adherence to plastic in standard
culture conditions; (2) expression of the surface molecules
CD73, CD90, and CD105 in the absence of CD34, CD45,
HLA-DR, and CD14 or CD11b and CD79a or CD19 sur-
face molecules, as assessed by flow cytometry analysis; (3)
capacity for differentiation to osteoblasts, adipocytes, and
chondroblasts in vitro [18]. These criteria were established to
standardize human (h)MSC isolation but may not uniformly
apply to other species.
Furthermore, murine species obtained from 5 strains
were similar to human and rat MSCs in terms of expansion
under adherent conditions, single-cell-derived colony for-
mation assay, and multipotent differentiation to osteoblasts,
adipocytes, and chondroblasts in vitro [19]. However, the
cells from the 5 strains differed in their media require-
ments for optimal growth, rates of propagation, and pres-
ence of the surface epitopes CD34 (B1/6+++, FVB/N++,
and BALB/c and DBA1+ and hMSC−), stem cell antigen-
1 (Sca-1; B1/6 and FVB/N+++; BALB/c−, DBA1+, and
hMSC not available), CD90 (B1/6, FVB/N, and BALB/c and
DBA1− and hMSC+++), and vascular cell adhesion molecule
1/CD106 (VCAM-1; B1/6, FVB/N, hMSC+++, and BALB/c
and DBA1+). CD45 and CD11b negativity are observed
in all murine strains and human MSCs. The differences
among MSCs from different strains may explain some of
the conflicting data published on the engraftment of mouse
MSCs or other bone marrow cells into nonhematopoietic
tissues.
3.1. Isolation and Sources of MSCs. Historically, MSCs were
isolated from bone marrow (BM-MSC) and spleen from
guinea pigs by Friedenstein and colleagues [20]. They
observed that MSCs were plastic adherent cells and were
capable of forming single-cell colonies. When BM-MSCs
were expanded in culture, round-shaped colonies resembling
fibroblastoid cells formed and were identified by the Colony
Forming Unit-fibroblast (CFU-f) assay.They were the first to
demonstrate that MSCs exhibited multipotential capacity to
differentiate into mesoderm-derived tissues.
MSCs can be isolated (a) by using a gradient centrifuga-
tion (Ficoll or Percoll) to separate nonnucleated red blood
cells from nucleated cells; (b) by taking advantage of their
ability to adhere to plastic; or (c) by the ability of monocytes
to be separated fromMSCs by trypsinization [21].
During the 1980s, MSCs were shown to differentiate into
osteoblasts, chondrocytes, adipocytes, and muscle [22]. In
the 1990s, it was documented that MSCs were able to differ-
entiate into ectodermal-derived tissue [23, 24]. During the
early 21st century, in vivo studies demonstrated that human
MSCs differentiated into endodermal-derived cells [25, 26],
cardiomyocytes [27], and renal mesangial and epithelial
tubular cells [28, 29]. However, their efficiency to differentiate
into other tissues is extremely low in vivo and therefore is not
the main mechanism of tissue repair.
MSCs can be isolated fromBM, adipose tissue (ADMSC),
umbilical cord blood (UCB-MSC), and other tissues. In BM,
1 in 10,000 nucleated cells is a MSC. To note, one gram of
aspirated adipose tissue yields approximately 3.5× 105–1× 106
ADMSCs. This is compared to 5 × 102–5 × 104 of BM-MSCs
isolated from one gram of bone marrow aspirate [30].
MSCs possess ubiquitous distribution in perivascular
niches and can be derived and propagated in vitro from
different organs and tissues (BM, brain, spleen, liver, kidney,
lung, muscle, thymus, pancreas, cord blood, amniotic fluid
and placental membranes, and large vessels, such as aorta
artery and vena cava) [31, 32].
MSC cell populations originating from different tissues
and organs exhibit similar morphology and, to a certain
extent, surface marker profile [31]. On the other hand, differ-
entiation assays indicate some variation among cultures in
the frequency of cells that possess the capacity to differen-
tiate into osteogenic or adipogenic lineages. For example,
vena cava derived MSCs were very efficient at depositing
mineralized matrix, whereas muscle-derived MSCs showed
little efficiency, although an inverse capacity of adipocyte
differentiation was observed with these cells [31]. In contrast,
the adipogenic differentiation observed in lung-, brain-, and
kidney-derived MSCs seemed to be less efficient. Likewise,
UCB-MSCs exhibit significantly stronger osteogenic capacity
but lower capacity for adipogenic differentiation in compar-
ison to BM-MSCs [33]. Of importance, ADMSCs exhibit
similar capacity of differentiation when compared to BM-
MSCs [34].
3.2. Paracrine Signaling and Immunomodulatory Effects of
MSCs. Notably, the frequency of MSC engraftment and dif-
ferentiation in different organs is low compared to the robust
functional recovery observed after cell transplant, which
has raised questions as to whether MSC engraftment and
differentiation is the leading mechanism of action. MSCs
secrete a wide array of cytokines and growth factors, which
can suppress the immune system, fibrosis oxidative stress, and
apoptosis and enhance angiogenesis [35].
The effects of MSCs on innate and adaptive immunity
have been reported in the literature. MSCs modulate the
innate function of monocytes, macrophages, natural killer
(NK) cells, and dendritic cells (DCs). They are capable of
modifying the maturation of DC, thereby inhibiting their
antigen-presenting function an inducing the generation of
tolerogenic DCs. Importantly, MSCs show intermediate
expression of MHC I (Major Complex of Histocompatibility)
and do not express MHC II on their surface, which reduces
their antigenicity and increases their tolerability in allogeneic
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transplant [36–38]. Furthermore, MSCs are capable of
suppressing T lymphocytes proliferation and inducing
FOXP3+CD4+ regulatory T lymphocytes (Tregs). Mediators
of Treg generation include indoleamine 2,3-dioxygenase
(IDO), prostaglandin E2 (PGE2), and IFN-𝛾. In addition,
MSCs inhibit the proinflammatoryTh17 cell activity.
To note, MSC effect on lymphocytes B cell has been
scarcely studied and contradictory, yet it appears that this
interaction occurs not only by the modulation of T-helper
lymphocyte activity by MSCs, but also by a direct inhibitory
mechanism by MSC in B lymphocyte activation [39].
Although BM-MSCs, ADMSCs, and UCB-MSCs equally
hamper T lymphocyte, B lymphocyte, and NK cell-mediated
immune response by preventing their acquisition of lym-
phoblast characteristics, activation, and changing the expres-
sion profile of proteins with an important role in immune
function, UCB-MSCs do not inhibit B cells activation [34,
40].
Although these studies suggest that the use of MSCs in
regenerative therapies could be successful, the mechanisms
responsible for the tolerance of the host immune system to
MSCs are not fully understood. Moreover, all these mecha-
nisms are interrelated and involve both direct cell-cell contact
and indirectmechanisms, through the production and release
of soluble factors, such as cytokines and hormones.
4. Mesenchymal Stem Cells (MSCs) in
Diabetic Nephropathy (DN)
4.1. MSC Therapy in Small and Large Animals. In 2001,
the Animal Models of Diabetic Complications Consortium
(AMDCC) was created by National Institutes of Health to
develop and characterize models of diabetic nephropathy.
Hence, AMDCC defined the following criteria for validating
a progressive mouse model of DN [41]: (i) greater than
50% decline in GFR (glomerular filtration ratio) over the
lifetime of the animal; (ii) greater than 10-fold increase
in albuminuria compared to controls for the strain at the
same age and gender; (iii) pathology of kidneys that include
advanced mesangial matrix expansion +/− nodular sclerosis
and mesangiolysis; any degree of arteriolar hyalinosis; GBM
thickening by >50% over baseline, and tubule-interstitial
fibrosis.
The most promising strains to study DN, in accordance
with AMDCC recommendation, include the following:
(a) eNOS (endothelial nitric oxide synthase) deficient
(C57BL/6 and C57BLKS backgrounds) mice: to gen-
erate a model of type 1 DM, streptozotocin (STZ)
may be injected and to generate a model of type 2
DM; these mice can be crossed with C57BLKS (BKS)-
db/db mice
(b) bradykinin B2 receptor deficient (C57BL/6 and
C57BLKS backgrounds) mice: these mice can be
crossed with 𝐼𝑛𝑠2Akita/+ or BKS-db/db mice to study
DN. STZ also promotes DN in these transgenic
crossed mice
(c) decorin (inhibitor of TGF-𝛽) deficientmice (B6 back-
ground)
(d) NONcNZO10/LtJ mice: thesemice are derived from a
cross between nonobese nondiabetic (NON/lt) strain
the New Zealand Obese (NZO/H1Lt) mouse, which
provides a model of polygenic type 2 DM)
(e) FVB-OVE26 mice (FVB background): transgenic
model of early-onset of type 1 DM.
(f) Renin overexpression (129S6/SvEvTac background):
these mice express plasma renin near eight times nor-
mal and develop kidney and cardiovascular disease
Although these transgenic mice develop proteinuria and
renal histological abnormalities secondary toDN, they do not
reliably develop all of the features of human DN. However,
two recent models of type 1 and type 2 diabetes that reflect
humanDNwere reported [42, 43].These models can serve to
study the mechanisms that not only lead to the development
of DN, but also lead to testing cell therapy, gene therapy, and
pharmacologic drugs.
Notably, E1-DN mice were recently described as a model
of type 1 diabetes [42]. These mice express a kinase-negative
epidermal growth factor receptor in pancreatic islet cells and
are diabetic from 2 weeks of age due to impaired postnatal
growth of 𝛽-cell mass. By 10 weeks, they develop protein-
uria, mesangial expansion, thickening of GBM, widening
of podocyte foot process, podocyte apoptosis, glomerular
sclerosis, and reduction of nephrin expression.
The recently described BTBR (black and tan, obese,
tufted) ob/ob (leptin deficient) (BTBR𝑜𝑏/𝑜𝑏) mice with type 2
diabetes demonstrate key features of early podocyte loss and
mesangiolysis characteristic of human DN [43]. BTBR𝑜𝑏/𝑜𝑏
mice develop progressive proteinuria beginning at 4 weeks.
Characteristics of early DN, such as glomerular hypertrophy,
reduced podocyte density, and accumulation of mesangial
matrix, can be present by 8 weeks. Glomerular lesions similar
to those of advanced human DN are present by 20 weeks. By
22 weeks, an approximately 20% increase in basement mem-
brane thickness and a >50% increase in mesangial matrix
can be detected and are associated with diffuse mesangial
sclerosis (focally approaching nodular glomerulosclerosis);
focal arteriolar hyalinosis, mesangiolysis, and focal mild
interstitial fibrosis are present.
To note, pharmacologic induction of DN with STZ,
with or without accelerating factors, such as high fat diet,
uninephrectomy, or use of the nonobese diabetic strain
(NOD) strain has been the most common rodent model of
DN to study the potential therapeutic of MSCs [35].
Yet pharmacological therapy with angiotensin converting
enzyme inhibitors and angiotensin II receptor antagonists,
glucose and blood pressure control, and lifestyle modifica-
tions [3, 44] are standard-of-care for diabetic individuals; the
search for complementary therapeutic approaches to curtail
DN progression is required.
MSCs administration is reported to ameliorate renal
and pancreatic parameters in terms of dysfunction and
morphological abnormalities, as reported in Table 1 [45–60].
MSCs are generally transient cells that exist briefly in the
host and cannot be identified after a few days or possibly
a week or two. Their safety as allogeneic cell transplants
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Table 1: Preclinical studies in rodents to test the potential of MSCs in DN.
MSC isolation/type
of transplant Model of DN and groups
Number of
injections/route of
delivery
Number of
cells
injected
Results Reference
h-BM-MSCs,
xenotransplant
STZ-induced type 1
NOD/scidmice: normal,
DN, DN + hMSC
Single dose,
intracardiac 2.5 × 10
6
DN + hMSC versus DN:
↑ pancreatic insulin content and islet cell
number
↓ renal macrophage infiltration
Improvement in renal histology
[45]
BM-MSCs,
allogeneic
STZ-induced type 1
diabetes C57BL/6 mice: DN
+ vehicle and DN +MSC
Single dose,
IV 0.5 × 10
6
DN +MSCs versus DN:
↓ blood glucose levels
↓ albuminuria and glycosuria
Improvement in renal and 𝛽-cell
histology
[46]
BM-MSCs,
allogeneic
STZ-induced type 1
diabetes C57BL/6 mice:
Control, DN + vehicle, DN
+ MSC
Two doses (interval
of 20 days),
IV
0.5 × 106
DN +MSCs versus DN:
↓ albuminuria
Improvement in renal histology
No improvement in 𝛽-cell function and
histology
[47]
BM-MSCs,
allogeneic
STZ-induced type 1
diabetes Sprague-Dawley
Rats:
DN control, MSC, CSA,
MSC + CSA (MSCA)
single dose,
intracardiac 2 × 10
6
MSCA group versus DN:
↓ blood glucose levels
↓ albuminuria
Improvement in renal mass index
[48]
ADMSCs,
autologous
STZ-induced type 1
diabetes Sprague-Dawley
Rats:
Control non-diabetic, DN
+ vehicle, ADMSC + DN
Single dose,
IV 1 × 10
7
DN + ADMSCs versus vehicle:
↓ renal p-p-38, p-ERK and p-JNK
↓ renal MDA and carbonyl protein
↓ renal TNF-𝛼, IL-1𝛽, IL-6
↓ renal MnSOD and CuZn-SOD
[49]
h-UCB-SCs,
xenotransplant
STZ-induced type 1
diabetes Sprague-Dawley
Rats: control, DN, DN +
h-UCB-SC
Single dose,
IV 1 × 10
6
DN + h-UCB-SCs versus DN:
↓ blood glucose levels
↓ albuminuria
↓ renal fibronectin, 𝛼-SMA
↑ renal E-cadherin
[50]
h-UCB-SCs,
xenotransplant
STZ-induced type 1
diabetes Sprague-Dawley
Rats: control, DN, DN +
h-UCB-SC
Single dose,
IV 5 × 10
5
DN + h-UCB-SCs versus DN:
↔ blood glucose levels
↔ albuminuria
Improvement in renal histology
↓ renal TGF-𝛽1, 𝛼-SMA
↑ renal E-cadherin, BMP-7
[51]
BM-MSCs,
allogeneic
STZ-induced type 1
diabetes Sprague-Dawley
Rats: Normal control, DN +
MSC and DN + medium
Single dose, left
renal artery 2 × 10
6
DN +MSCs versus DN + medium:
↔ blood glucose levels
↓ kidney weight, kidney/body weight,
creatinine clearance
↓ albuminuria
Improvement in renal histology
↑ renal nephrin, podocin, VEGF, BMP-7
[52]
BM-MSCs,
allogeneic, UTDM
STZ-induced type 1
diabetes Sprague-Dawley
Rats: Normal control, DN +
PBS, DN + UTMD, DN +
MSC, DN + MSC + UTMD
Single dose,
IV 1 × 10
6
MSC and MSC + UTMD versus DN and
UTMD:
↓ blood glucose levels
↑ plasma insulin
Attenuated 𝛽-cell damage
↓ albuminuria
↓ renal TGF-𝛽1
↑ renal synaptopodin, IL-10
After UTMD: MSC homing was
increased to kidneys (∼2x)
[53]
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Table 1: Continued.
MSC isolation/type
of transplant Model of DN and groups
Number of
injections/route of
delivery
Number of
cells
injected
Results Reference
BM-MSCs,
allogeneic
STZ-induced type 1
diabetes Wistar Rats:
Normal control, DN +
vehicle, DN + MSC
2 doses
(1 week a part),
IV
2 × 106
DN +MSCs versus DN:
↓ blood glucose levels
↓ albuminuria
↓ creatinine clearance
Improvement in renal histology
↓ renal MCP-1, ED-1, IL-1𝛽, IL-6, TNF-𝛼
↑ renal HGF
[54]
BM-MSCs,
allogeneic
STZ-induced type 1
diabetes Wistar rats: DN,
DN + MSC, DN + Insulin,
DN + Probucol
2 doses
(1 week a part),
IV
2 × 106
DN +MSCs versus DN:
↓ blood glucose levels
↓ albuminuria
↓ creatinine clearance
↓ kidney/body weight
Improvement in renal histology
↓ renal fibronectin and collagen I
↓ renal MDA content
↓ renal TGF-𝛽1
↓ renal ROS fluorescence
↑ renal SOD activity
↓ cellular glucose uptake mediated by
GLUT1 in kidneys
[55]
BM-MSCs,
allogeneic
STZ-induced type 1
diabetes albino rats:
Control, DN, DN + PBS,
DN + MSC
Single dose,
IV 1 × 10
6
DN +MSCs versus DN:
↓ blood glucose levels
↓ albuminuria
↓ body weight
↓ serum creatinine and urea
↑ renal VEGF and anti-apoptotic bcl2
↓ renal TNF-𝛼, pro-apoptotic Bax,
TGF-𝛽
Improvement in renal histology
[56]
BM-MSCs,
allogeneic
Normal control, DN +
saline, DN + MSC
2 doses
(1 week a part),
IV
2 × 106
DN +MSCs versus DN:
↓ blood glucose levels
↓ albuminuria
↓ kidney/body weight
↓ creatinine clearance
Improvement in renal histology
↓ renal collagen I, collagen IV, 𝛼-SMA,
TGF-𝛽, P-smad3/smad2/3
↑ renal E-cadherin, BMP7
[57]
BM-MSCs,
allogeneic
SDF-1-loaded
microbubbles
STZ-induced type 1
diabetes Sprague-Dawley
Rats:
Control, UTMD, UTMD +
MSC
Single dose,
IV 1 × 10
6 Improvement in renal histology [58]
BM-MSCs,
allogeneic
STZ-induced type 1
diabetes C57BL/6 mice: DN
+ vehicle, DN + MSC
Single dose,
IV 0.5 × 10
6
DN +MSCs versus DN:
↓ kidney
↓ kidney/body weight
↓ serum creatinine, urea, and plasma
cystatin C
↓ renal collagen I and fibronectin
↓ renal tubular apoptotic index, ROS
total, lipid peroxidation, oxidative protein
damage, F4/80 positive cells
↑ renal nephrin, tubular Ki67
proliferation index
↑ plasma bFGF, EGF, HGF, IL-6, and
IL-10
Improvement in renal histology
[59]
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Table 1: Continued.
MSC isolation/type
of transplant Model of DN and groups
Number of
injections/route of
delivery
Number of
cells
injected
Results Reference
BM-MSCs,
allogeneic
STZ-induced type 1
diabetes Sprague-Dawley
rats: control, DN, DN +
MSC
Single dose,
IV 2 × 10
6
MSCs + DN versus DN:
↔ blood glucose levels
↓ albuminuria
↓ kidney weight
↓ serum creatinine
↓ renal PAI-1, TGF-𝛽1, Smad3
[60]
MSCs: mesenchymal stem cells; BM-MSC: bone marrow-derivedMSCs; h-BM-MSC: human bone marrow-derivedMSC; ADMSC: adipose-derivedMSCs; h-
UCB-SCs: human umbilical cord blood-derived stem cells; DN: diabetic nephropathy; STZ: streptozotocin; CSA: cyclosporine; PBS: phosphate buffered saline;
IV: intravenous; 𝛼-SMA: 𝛼-smooth muscle actin; bFGF: basic fibroblast growth factor; BMP-7: bone morphogenic protein-7; EGF: epidermal growth factor;
HGF: hepatocyte growth factor; MCP-1: monocyte chemoattractant protein-1; SDF-1: stromal derived factor-1; TGF-𝛽: transforming growth factor 𝛽; TNF-𝛼:
tumor necrosis factor-𝛼; VEGF: vascular endothelial growth factor; IL: interleukin; SOD: superoxide dismutase;MDA:malondialdehyde; ROS: reactive oxygen
species; UTMD: ultrasound-targeted microbubble destruction; PAI-1: plasminogen activator inhibitor-1.
may be closely related to their short-term existence. Their
anti-inflammatory properties, homing to sites of damage and
inflammation, and their trophic influence on tissue repair
have made them a promising strategy for clinical studies.
Although MSC therapy has already been reported to
ameliorate kidney and pancreatic injury, many difficulties
must be overcome to successfully implement that cell therapy.
These difficulties include the definition of the most appro-
priated route for cell delivery and the number of cells to
be injected, the improvement of MSC homing to damaged
kidneys, the comprehension of MSC-host cells interaction,
and the adverse effects of MSC engraftment (in vivo mal-
differentiation and tumor formation).
MSC delivery route is a crucial aspect of cell therapy. As
reviewed elsewhere, arterial route for progenitor/stem cell
delivery promotes kidney regeneration more efficiently than
intravenous route [61]. In intravenous route, the number of
cells, multiple intravenous injections, and cell size increase
the chance of pulmonary trapping [62, 63]. Although intra-
parenchymal administration of progenitor/stem cells also has
beneficial effect on kidney repair, this route is less practical for
clinical application, especially when renal disease is diffuse
[61].
Stromal-derived factor (SDF-1) or CXCL12 binds to
two receptors, CXCR4 and CXCR7. SDF-1/CXCR4 plays an
important role in MSCs [64] and renal progenitor cell [65]
migration to damaged kidney. When combined with ultra-
sound-targetedmicrobubble destruction (UTMD), amethod
that increases renal interstitial permeability, exogenous SDF-
1 can be released in the kidneys and improve MSC homing
[58].
An emerging approach of MSC-based therapies includes
the understanding of exosomes role in tissue regeneration.
Exosomes are naturally occurring secreted membrane vesi-
cles (30–40 to 100–120 nm) with a ubiquitous presence in
biological fluids and an intrinsic homing ability. These extra-
cellular vesicles are considered as importantmediators of cell-
to-cell communication, mediating the effects of MSCs on
target cells, such as transfer of receptors, proteins, and genetic
information (mRNA and microRNAs), as well as possessing
a direct stimulation on target cells [66]. In preclinical studies,
the use of MSC-derived microvesicles is associated with
improved organ function following acute injury and may
be useful for inhibiting tumor growth [67]. The therapeutic
effect of these microvesicles seem to be superior to the effect
observed when conditioned-medium is infused in acute
injury kidney models [68], although others reported better
outcomes with conditioned-medium than with microvesicles
in chronic kidney disease in rats [69]. In DN setting, the lit-
erature is poor regarding the therapeutic potential of micro-
vesicles. Furthermore, improved preclinical study quality in
terms of treatment allocation reporting, randomization, and
blinding will accelerate the progress towards clinical trials
that should assess feasibility and safety of this therapeutic
approach in humans.
On top of that, a key aspect that can adversely affect
the therapeutic potential of MSCs is the inflammatory envi-
ronment at the site of the injury, since it can impact the
survival and the engraftment of these cells. Furthermore,
anti-inflammatoryM2macrophage-associated cytokines (IL-
10, TGF-𝛽1, TGF-𝛽3, and VEGF) support the growth of
MSCs, whereas proinflammatory M1 macrophage-associated
cytokines (IL-1𝛽, IL-6, TNF-𝛼, and IFN-𝛾) inhibit MSC
growth in vitro [70]. That observation indicates that the
timing of MSC injection is crucial for the success of tissue
repair.
Although there is evidence that MSCs can differentiate
in vitro into mesangial cells when a coculture system of
MSCs and oxidant-injured mesangial cells is established [71],
further studies are required to improve our understanding in
the crosstalk between MSC-damaged mesangial cells in vivo.
Taking a step forward, since companion or domesti-
cated animals naturally develop many diseases that resemble
human conditions, they represent, therefore, a novel source
of preclinical models. Several diseases have been reported
mainly in dogs, but also in cats, and include the chronic
kidney disease (CKD) model. The majority of these studies,
although uncontrolled, reported that MSCs are potential
candidates for regenerating the damaged tissue, as reviewed
by Hoffman and Dow [72].
Furthermore, feline chronic kidney disease (CKD) repre-
sents an ideal model to study the impact of drugs and cell
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therapy to reduce tubule-interstitial fibrosis and glomeru-
losclerosis, since CKD develops in 80–90% of these animals
by age of 15 years. However, ADMSCs (adipose-derived
MSCs) injection into cats via intravenous route, 2–4 ×
106 cells, repeated three times, was not associated with
improvement in renal functional parameters [73, 74]. To note,
higher doses of ADMSCs (4 × 106 cells) lead to adverse
events during infusion, such as vomiting. Nonetheless, other
routes of cell infusion are required to reach definitive con-
clusions about the therapeutic potential of MSC in feline
CKD.
4.2.MSCTherapyHumans. Thenumber of registered clinical
trials worldwide and MSC-based product Investigational
New Drug (IND) submissions to Food and Drug Adminis-
tration (FDA) have been increasing recently, as well as the
diversity in donor and tissue source [75]. Interestingly, the
proportion of IND submissions that evaluated BM-MSC-
based products was 100% through 2007 but decreased to
∼55% by 2012. The number of ADMSC-based product INDs
increased significantly since 2011, with a 3-fold increase
between 2011 and 2012 alone.
Several types of stem cells have been tested in a wide
range of diseases and injuries, mainly in phase I/II tri-
als: human embryonic stem cell-derived retinal pigmented
epithelial cells for macular degeneration; human neural
stem cells for stroke/cervical spinal cord injury; endothe-
lial stem/progenitor cells for pulmonary arterial hyperten-
sion; and placental stem cells for stroke/rheumatoid arthri-
tis/peripheral artery disease, for example, [76].
There is considerable heterogeneity in MSC protocols
and a variety of sources used to isolate and manufacture the
MSC populations for clinical trials [76]. The majority of the
MSC trials are allogeneic cells and these trials are happening
in the USA, Europe, and China: phase 1 only (26%), phase
1/2 (40.6%), phase 2 only (22.5%), phase 2/3 (3.8%), phase
3 only (6.7%), and phase 4 only (0.3%). The indications
of MSC-based therapy in 352 registered trials comprised
bone/cartilage, heart, neurons, immune/autoimmune, dia-
betes/kidney, lung, liver, and gastrointestinal trials. When
type 2 diabetic patients (𝑛 = 22) were treated with allo-
geneic Wharton’s Jelly-derived MSCs (1 × 106/kg) by both
intravenous and intrapancreatic routes, a reduction in
glucose and glycated haemoglobin levels associated with
decreased systemic inflammation, for example, low levels of
IL-1𝛽 and IL-6, and T-lymphocyte counts (CD3 and CD4)
were observed at 12-month follow-up [77]. Likewise, C-
peptide levels ameliorated after MSC treatment and insulin
requirement decreases by ∼50%.
A key aspect of MSC-based therapy is the isolation
of MSCs from diabetic individuals for autologous trans-
plant. It is reported that ADMSC from diabetic donors
exhibits higher levels of cellular senescence and apoptosis
when compared to nondiabetic ADMSC, as well as reduced
capacity of osteogenic and chondrogenic differentiation [78].
Hence, allogeneic versus autologous MSC-based transplanta-
tion requires further investigation in DN setting. In patients
with ischemic cardiomyopathy, allogeneic and autologous
BM-MSCs were equally safe and effective [79].
Moreover, further characterization of MSC-based manu-
factured products to better understand the existence, pheno-
type, andMSC subpopulations is crucial for advancingMSC-
based therapies.
In addition, some obstacles need to be overcome in order
to provide safety for MSC-based therapies, such as cytogenic
aberrations in mice-derived MSC (C57BL/6 and BALB/c)
after several passages in vitro [80] and their malignant
transformation in vivo either after injection [81] or by pro-
moting growth of a preexisting tumor [82]. For humanMSCs,
malignant transformation of these cells has not been noted
to date in clinical trials [36, 76]. Of importance, beneficial
effect of MSCs can be offset by a long-term adipogenic mal-
differentiation accompanied by glomerulosclerosis [83].
5. Perspectives
Although there have been major advances in the under-
standing of the molecular mechanisms that contribute to
the development of DN, current best practice still leaves a
significant treatment gap.Next, we discuss someperspectives,
combined with current available treatment and/or MSC-
based approach, that can ultimately contribute to halting the
progression of DN, as summarized in Figure 1.
5.1. Pharmacologic Therapy. No currently available treat-
ments can prevent the development of diabetic nephropathy.
The established therapeutic strategies are mainly based on
strict control of glucose levels and blood pressure and block-
ade of the RAAS.These strategiesmay slow the progression of
renal damage, butmany patients still have progressive disease
[84]. Although novel agents, such as sulodexide (ameliorates
the abnormalities in the glomerular basement membrane
and mesangial matrix), pyridoxamine (inhibitor of AGE
formation), alagebrium (ACE cross-linker breaker), and
ruboxistaurin (inhibitor of PKC-𝛽), have been tested in phase
II studies, their benefit still requires further investigation [85].
The clinical trial involving aliskiren, a renin inhibitor, was
stopped prematurely due to adverse events (hyperkalemia,
hypotension, and cardiac arrest) and due to lack of benefit
when compared to placebo [86].
A new approach to the management of type 2 DM
involves the reduction of renal glucose reabsorption through
inhibition of the high-capacity and low-affinity sodium
glucose cotransporter (SGLT2), found in the brush border
of the first segment of the proximal convoluted tubules
[87]. Approximately 160–180 g/day of glucose is filtered and
reabsorbed by the kidneys in healthy individuals, reaching
∼100–230 g/day with SGLT2 inhibitors [88]. Likewise, uri-
nary glucose excretion is <0.5 g/day in health individuals and
increases to∼50–80 g/day with those drugs. SGLT2 inhibitors
promote a reduction of 0.59–0.82% in glycated hemoglobin
and moderate reduction in body weight (−2.1 to −2.5 kg) and
systolic blood pressure (−2.9 to −5.2mmHg) [89].
Mechanistically, SGLT2 inhibitors (empagliflozin, dapag-
liflozin, and canagliflozin) reduce proximal tubular sodium
reabsorption, thereby increasing distal sodium delivery to
the macula densa, which has been shown to activate tubu-
loglomerular feedback, leading to afferent vasoconstriction
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Diabetic nephropathy progression to end-stage renal disease (%)
Novel therapeutic approaches
(iii) Microbiote modulation
(i) Drugs: sodium-glucose
cotransporter (SGLT2)
and incretins
(ii) Autophagy modulation
(iv) Nanotechnology
(v) Drugs and/or MSC
therapy: effects on endogenous
progenitor/stem cells∼30–40%
Classical treatment
(vi) Smoke cessation
(v) RAAS blockade
(iv) Blood pressure control
(iii) Physical activity
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(i) Glycemic control
MSC effects on kidney
(ii) Trophic factors:
(i) Immunomodulation:
(iii) Oxidative stress:
(iv) Renal cell injury:
synaptopodin, and E-cadherin
(v) Fibrosis:
types I and IV, and 𝛼-SMA
↓ TGF-𝛽1, PAI-1, collagen
↑ Bcl-2 (antiapoptotic)
↓ BAX (proapoptotic)
↑ Nephrin, podocin, WT-1,
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↑ SOD
↓ MCP-1 (macrophage infiltration)
↑ IL-10 (anti-inflammatory)
↓ IL-1𝛽, IL-6, and TNF-𝛼 (proinflammatory)
↑ HGF, EGF, VEGF, and BMP-7
Figure 1: Current treatment to prevent DN, MSC-based therapeutic approaches, and perspectives to halt the progression of DN.
and a decrease in the hyperfiltration and intraglomerular
pressure [88]. A mild osmotic diuresis also occurs.
The randomized controlled trial EMPA-REG Outcomes
with a 3.1-year follow-up documented that empagliflozin
leads to significantly lower rates of death from cardiovascular
causes (38%), hospitalization for heart failure (35%), and
death from any cause (32%) [90]. Empagliflozin was also
associatedwith lower rates of hyperglycemia and lower values
for weight and blood pressure, without an increase in cardiac
rate, than was placebo.
Regarding renal outcomes in the EMPA-REG trial,
empagliflozin was associated significantly with lower rates
of incident or worsening nephropathy (12.7% versus 18.8%)
[91]. Doubling of the serum creatinine and renal replacement
therapy initiation decreased by 44% and 55%, respectively. To
note, ∼80% of the patients in the empagliflozin and placebo
groups were taking standard-of-care drugs (angiotensin-con-
verting enzyme inhibitors or angiotensin-receptor block-
ers) at baseline, whereas the clearance of creatinine was
∼48mL/min/1.73m2. Urinary albumin-to-creatinine ratio
(mg/g creatinine) was < 30 in 46.6%, 30–300 in 33.8%, and
>300 in 18.9% and did not change with empagliflozin.
In humans, the only adverse effect was genital and urinary
infection in the empagliflozin group [88, 90, 91]. In addition,
SGLT2 inhibitors exhibit limited action in patients with
severe renal impairment.
In BTBR𝑜𝑏/𝑜𝑏 mice, empagliflozin treatment for 12 weeks,
starting at age of 8 weeks, enhanced glycosuria and decreased
blood glucose and proteinuria, independently of angiotensin
II-induced hypertension [92]. Renal effects were explained
by structural improvement (reduction in glomerular tuft area
and mesangial expansion) and decreased renal expression of
monocyte chemoattractant protein-1 (MCP-1), regulated on
activation, normal T cell expressed, and secreted (RANTES)
chemokine and IL-6.
In the db/dbmice, amodel of type 2DNpossesses a spon-
taneous mutation of the leptin receptor and is characterized
by polyphagia, obesity, insulin resistance, hyperglycemia, and
pancreatic 𝛽-failure; empagliflozin leads to a decrease in
the glomerulosclerosis index and renal expression of TGF-
𝛽1, without affecting proteinuria, plasmatic cystatin C, and
urinary markers (KIM-1 and NGAL) [93]. Tubule-interstitial
fibrosis decreased when empagliflozin was associated with
metformin.
Glucagon-like peptides 1 (GLP-1) receptor agonists and
DPP-4 (dipeptidyl peptidase-4) inhibitors (incretin-based
therapies) are also currently available strategies to prevent
DN. One of these drugs, liraglutide, can ameliorate kidney
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fibrosis in a STZ-induced DNmodel in ED-1 mice by inhibit-
ing TGF-𝛽2-mediated endothelial-mesenchymal transition,
a key mechanism that has emerged as an important source
of matrix-producing fibroblasts [94]. That mechanism seems
to be related to microRNA29 induction. Liraglutide can also
contribute to decrease proteinuria in STZ-induced DN in
Wistar rats by reducing the renal inflammation-mediated by
NF-𝜅B, TNF-𝛼, MCP-1, IL-6, and INF-𝛾 and by increasing
eNOS phosphorylation, eNOS activity, and NO production
[95]. Likewise, inhibiting DPP4 suppresses renal oxidative
stress and receptor for AGE products in the db/dbmice [96].
Hence, inhibiting DPP-4 may be a therapeutic target for
treating kidney fibrosis in diabetes. MSC-based therapy may
provide additional benefit in preventing DN when combined
with SGLT2 and DPP-4 inhibitors.
5.2. Modulation of Autophagy. Podocytes exhibit high levels
of constitutive autophagy, a pathway that delivers damaged
proteins and organelles to lysosomes, representing a key pro-
tective mechanism against podocyte aging and glomerular
injury [97]. Therefore, modulating autophagy represents a
promising target therapeutic strategy to slow the progression
of DN.
Tight balance of mTOR activity is crucial for podocyte
homeostasis. mTORC1-Raptor regulates autophagy, whereas
mTORC2-Rictor is important for cell survival, metabolism,
proliferation, and cytoskeleton maintenance. Genetic dele-
tion of mTORC1 podocyte leads to proteinuria and pro-
gressive glomerulosclerosis in mice [98]. That progression is
aggravated by simultaneous deletion of mTORC2.
Conversely, mTORC1 is highly activated in podocytes
of diabetic mice and patients and may be involved in the
mechanisms of diabetes-related autophagy inhibition, which
ultimately leads to early glomerular hypertrophy and hyper-
filtration in diabetic nephropathy (DN) setting [98]. Hence,
whenmTORC1 is genetically deleted in podocytes of diabetic
mice, the progression of glomerular disease is attenuated [98].
Likewise, SRL, a potent mTORC1 inhibitor, can also ame-
liorate glomerular lesions in diabetic rat [99]. Furthermore,
abnormal mTORC1 activation causes mislocalization of slit
diaphragm proteins and induces an epithelial-mesenchymal
transition-like phenotypic switch with enhanced endoplas-
mic reticulum (ER) stress [100]. Collectively, these data
indicate that genetic deletion or reduced activity of mTORC1
may protect podocyte and prevent DN-induced glomeru-
losclerosis.
5.3. Fecal Microbiota Modulation. The intestinal microbiota
is a complex ecosystem that affects human metabolism
and may contribute to the development of obesity, insulin
resistance, and subsequent type 2 diabetes. The ability of the
intestinalmicrobiota to affect hostmetabolism ismediated by
at least four components: dietary/nutrients intake, bile acids
dehydroxylation, short chain fatty acid (SCFA) metabolism,
and gut microbiota composition [101].
Of importance, metagenomic sequencing studies in Chi-
nese and European individuals with type 2 DM indicate that
functional alterations of their gut microbiome, for example,
dysbiosis, might be directly associated with type 2 DM
development [102, 103]. Dysbiosis leads to an increase in
lipogenesis in liver and LPS- (lipopolysaccharide-) mediated
inflammation in adipose tissue, as well as a decrease in insulin
sensitivity and fatty oxidation in muscle [101]. Mechanisti-
cally, a reduced amount of butyrate-producing bacteria [102]
and the Akkermansia muciniphila bacteria [104] is observed
in human and mice with type 2 diabetes.
Therapeutic interventions thatmanipulate themicrobiota
such as prebiotics, probiotics (live microorganisms), and
fecal microbiota transplantation (FMT; infusing intestinal
microbiota from lean donor) may have benefits in improving
glucose metabolism and insulin resistance in the host [101,
104–108]. FMT in humans with metabolic syndrome has
beneficial effects on the recipients’ microbiota composition
(increase in SCFA-producing bacteria), with a concomitant
improvement in insulin sensitivity [109]. These effects may
be mediated by normalization of SCFA-producing bacteria.
Likewise, FMT from obese to lean mice lead to an increase of
20% in the adiposity [110].
However, it is yet to be proved whether intestinal micro-
biota plays a causal role in the pathogenesis of obesity and
insulin resistance, as well as whether MSC-based therapy can
modulate intestinal microbiota towards a less inflammatory
environment in DN setting.
5.4. Nanotechnology. Nanoparticles possess numerous medi-
cal applications and are emerging as a class of carriers for drug
and gene delivery.
As previously reported, cell-based strategy utilizing
MSCs therapy is very promising for tissue regeneration [111],
including DN [35, 58]. MSCs show preferential migration
toward sites of inflammation, injury, and cancer, suggesting
that these cells may be attractive hypoimmunogenic cellular
vehicles for drug and gene delivery [112], as well as trophic
factors to damaged diabetic kidney.
The metallic nanoparticles is one of the most utilized,
especially due the versatility of this platform, absent immuno-
genicity, and the ability to allow the cell tracking in vivo by
single or multimodal imaging modalities [112–114].
However, understanding the nephrotoxic effect of the
nanoparticles is a key aspect to successfully combine that
technology with MSC-based therapy. Cytotoxic effects of
metallic nanoparticles evaluated in human renal cell lines
(IP15, glomerular mesangial cells and HK2, epithelial prox-
imal cells) were mediated by oxidative stress and were
associated with metal composition, particle scale, and metal
solubility [115]. That cytotoxicity is observed in vitro with
different types of nanoparticles (carbon, metal, and/or silica
nanoparticles) at both glomerular and tubular levels, such as
decreased cell viability, induction of oxidative stress, mito-
chondrial or cytoskeleton dysfunction, and cell membrane
and DNA damage [116].
Nanoparticle diameter is also a crucial aspect for targeting
kidney tissue. Therefore, gold-based nanoparticles of ∼75 ±
25 nm may target the mesangium of the kidneys [117]. Of
importance, MSCs transfected with nanoparticles of that size
may provide a novel strategy to target mesangial cells in DN,
yet mesangial expansion is the hallmark of early stages of
DN. Moreover, designing nanoparticles to target the kidney
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should take into account the notion of renal clearance and
glomerular filtration, because small nanoparticles (<10 nm)
can be filtered through glomerular filtration and be lost in
the urine. On the other hand, prolonged retention of the
nanoparticles inside the kidneys can be toxic due to excessive
nanoparticle uptake by renal cells.
These new insights utilizingMSC therapy combined with
nanoparticles are appealing and open new possibilities for the
treatment of injured renal cells in DN setting.
5.5. Kidney-Derived Stem/Progenitor Cells. Although exoge-
nous MSCs exhibit therapeutic potential, endogenous MSCs
do not migrate to damaged kidneys [118]. However, postnatal
tissues have reservoirs of specific progenitor/stem cells, which
contribute to maintenance and regeneration [119].
In human adult kidney, a hierarchical CD24+CD133+
population of progenitors cells organized in a precise
sequence along Bowman’s capsule (PECs, parietal epithelial
cells) was identified as a reservoir of cells that may con-
tribute to the turnover of senesced or injured podocytes by
proliferating, migrating, and differentiating from the urinary
to the vascular stalk [120]. However, lineage tracing studies
documented that their recruitment occurs mainly in juvenile
mice [121] and only a small fraction of these cells are recruited
to glomeruli in adult mice [122]. Likewise, PECs were not
involved in podocyte regeneration in models of glomerular
hypertrophy in adult animals [122], although these cells were
identified as a possible source of regenerating podocytes after
treatmentwith glycogen synthase kinase 3-𝛼 and 3-𝛽 (GSK3s)
inhibitor [123]. Of importance, abnormal proliferation of
these renal progenitors of the Bowman’s capsule can generate
hyperplastic glomerular lesions and scarring in collapsing
glomerulopathy and crescentic glomerulonephritis [124].
The leptin-deficient BTBR𝑜𝑏/𝑜𝑏 mouse provides a model
of advanced but reversible DN. Furthermore, leptin replace-
ment resulted in near-complete reversal of functional and
structural measures of advanced DN [125]. Hence, protein-
uria and accumulation of reactive oxygen species ameliorate
when leptin was administered, as well as the morphological-
related DN lesions, such as mesangial matrix expansion,
mesangiolysis, GBM thickening, and podocyte loss. To note,
PECs (identified with the podocyte markers Wilms tumor 1
and p57) contributed to generating new podocytes. On top of
that, inhibition of the renin-angiotensin-aldosterone system
(RAAS) did not reverse DN-related lesions, which can at least
in part explain the limited efficacy of RAAS inhibitors in
promoting repair of DN.
In addition, since paracrine factors have been proposed
as a key mechanism of benefit of MSC cell therapy, some
studies pointed out that MSC may stimulate endogenous
progenitor/stem cell proliferation and differentiation and
therefore contribute to tissue repair [126], although these
effects were not observed by others [127].
Understanding whyMSCs have the potential to stimulate
endogenous progenitor/stem cells may enable the future
development of pharmacoregenerative therapies, as well as
improving current cell therapy strategies. IfMSCs possess the
capacity to stimulate kidney-derived progenitor/stem cells
[128], including the recent c-Kit+ cell population described
recently by our group [129], further experiments in different
experimental models and in human tissue will be necessary
for a definitive picture of MSC in kidney regeneration.
5.6. MSC-Derived from Induced Pluripotent Stem Cells
(iPSCs). Induced pluripotent stem cells (iPSCs) are gener-
ated from somatic cells and represent a potentially inex-
haustible cell resource with a pluripotent potential similar to
embryonic stem cells. Functional MSCs derived from iPSCs
possess similarmesenchymal characteristics of the na¨ıve BM-
MSCs, such as positivity for typical mesenchymal markers
and negativity for endothelial and hematopoietic markers, as
well as trilineage differentiation properties [130]. Of impor-
tance, these iPSC-MSCs exhibit therapeutic potential inmod-
els of limb ischemia [131] and diabetic polyneuropathy [132].
However, their regenerative capacity duringDNdevelopment
requires further studies.
6. Conclusions
MSCs have several advantages for therapeutic purposes, such
as their ability to migrate to injured tissues, strong immuno-
suppressive effects, safety profile, and lack of ethical issues,
such as those related to the application of human embryonic
stem cells. Therefore, MSC-based therapy is expected to
become a promising strategy to slowDNprogression because
of their robust paracrine effects. Moreover, MSCs-based
therapy combined with new drugs and/or novel therapeutic
approaches, such as the modulation of fecal microbiota and
renal autophagy, and the design of nanoparticles to enhance
MSC effects will provide insightful strategies to prevent DN.
In addition, the better understanding of the crosstalk between
MSC and resident progenitor/stem cells may unveil a new
mechanism of MSC therapy.
Despite the similarities between the sources of MSCs
have already been documented, some important differences
should be taken into account when choosing theMSC source
for research or therapeutic purposes.Whether allogeneic and
autologous MSC-based therapies harbor the same potential
to treat kidney fibrosis in DN, there will be many MSC
products that will meet the criteria for registered products in
the established regulatory systems over the next years
To note, whether those findings in animals models will
translate into reduced proteinuria and glycemia in humans
with DN can only be determined in adequately powered,
randomized, and controlled trials.
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